Bridging genomic medicine and clinical practice: a cross-sectional analysis of knowledge, attitudes, and implementation of genetically tailored pharmacotherapy among doctors in a tertiary care hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20261953Keywords:
Pharmacogenomics, Doctors, Knowledge, Attitude, PracticeAbstract
Background: Pharmacogenomics is the study of how genetic variation influences drug response, impacting both efficacy and safety. It explains interindividual differences in drug action sometimes accounting for up to 95% of variability and has roots in discoveries like glucose-6-phosphate dehydrogenase deficiency related haemolysis with primaquine. By enabling personalized medicine, pharmacogenomics can optimize therapy, minimize adverse effects, and guide drug development. Despite its promise, challenges remain in genetic testing validity and defining clinical utility, especially for complex genes like CYP2D6.
Methods: This cross-sectional KAP study at Mysore Medical College and Research Institute surveyed doctors using a 25-item validated Google form questionnaire (6 demographic, 6 knowledge, 5 attitude, and 8 practice questions), with digital informed consent and ethical clearance. Data were distributed via WhatsApp groups, cleaned, and analysed using descriptive statistics across all domains.
Results: A total of 110 medical professionals participated in the survey. Awareness of the term pharmacogenomic testing was high (87.3%), but self-rated knowledge was mostly poor to fair (61.8%), and familiarity with major resources such as Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB was limited (>60% reporting poor awareness). Attitudes were largely positive, with more than half agreeing that pharmacogenomic testing can optimize drug choice and dosing and improve efficacy while reducing adverse drug reactions. However, practical use was low: only 12.7% reported institutional test availability and 81.8% had never recommended testing. Most respondents rarely or never discussed pharmacogenomics with patients (65.4%).
Conclusion: Overall, a significant gap exists between awareness and implementation, indicating a need for improved education, institutional support, and access to testing.
References
Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24(6):350-62.
Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol. 2001;52(4):345-7.
Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201-4.
Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529-37.
Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538-49.
Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet. 2004;5(9):645-56.
Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429(6990):464-8.
De Leeuw NKM, Shapiro L, Lowenstein L. Drug-induced Hemolytic Anemia. Ann Intern Med. 1963;58(4):592-607.
Drews J. Genomic sciences and the medicine of tomorrow. Nat Biotechnol. 1996;14(11):1516-8.
Burke W. Clinical Validity and Clinical Utility of Genetic Tests. Curr Prot Human Gene. 2009;60(1):1-7.
Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013;25(5):534-53.
Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genet Med. 2006;8(7):448-50.
Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med. 2011;13(12):987-95.
Andrade C, Menon V, Ameen S, Kumar Praharaj S. Designing and Conducting Knowledge, Attitude, and Practice Surveys in Psychiatry: Practical Guidance. Indian J Psychol Med. 2020;42(5):478-81.
Chen Z, Liew D, Kwan P. Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions. Neurology. 2014;83(22):2077-84.
Caudle KE, Klein TE, Hoffman JM, Müller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Curr Drug Metab. 2014;15(2):209-17.
Relling M, Klein T. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464-7.
Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. Clin Pharmacol Ther. 2014;95(4):376-82.
Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update. Clin Pharmacol Ther. 2014;95(5):499-500.
Phillips EJ, Mallal SA. HLA-B*1502 screening and toxic effects of carbamazepine. N Engl J Med. 2011;365(7):672.
Jia T, Wu C, Hu X, Li S, Zhang X, Cai Y, et al. Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China. JPM. 2022;12(12):2021.
Nawaz SMN, Ali M, Nadeem M, Rehman MA. Implementation of Pharmacogenomics Testing in Clinical Practice in Punjab, Pakistan: A KAP Survey of Healthcare Providers. Elementary Edu Online. 2021;20(4):1203-13.
Shre S, Arasan E. Knowledge Attitude and Practice Study of Pharma- cogenomics amongst Physicians of a Major Indian Metropolitan City. 2021. Available at: https://www.semanticscholar.org/paper/Knowledge-Attitude-and-Practice-Study-of-Pharma-of-Shre-Arasan/6ab968f063895a0201515db99295a705aaca6c3a. Accessed on 04 March 2026.
Nair A, Chacko J, Pillai S. A knowledge, attitude, and practices study of pharmacogenomics and its educational needs among doctors in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2018;10:1.
Muflih S, Alshogran OY, Al-Azzam S, Al-Taani G, Khader YS. Physicians’ Knowledge and Attitudes Regarding Point-of-Care Pharmacogenetic Testing: A Hospital-Based Cross-Sectional Study. Pharmgenomics Pers Med. 2021;14:655-65.
Downloads
Published
How to Cite
Issue
Section
